Hydroxyurea

Country of origin - Poland, Pliwa Krakow Poland, Polfa Poland
Pharm-Group - Synthetic antitumor agents of different groups

Manufacturers - Krakow Pharmaceutical Plant Polfa (Poland), Pliwa Krakow (Poland), Polfa (Poland)
International name - Hydroxycarbamide
Synonyms - Hydrea, Hydroxycarbamide Medak
Dosage forms - capsules 500 mg
Composition - Active ingredient - Hydroxycarbamide.

Indications for use:

1. Acute and chronic myeloid leukemia
2. Relapses of acute lymphoblastic leukemia in children
3. Osteomyelofibrosis
4. Erythremia
5. Thrombocytosis in the myeloproliferative syndrome program
6. Lymphogranulomatosis
7. Melanoma
8. Tumors of the head (excluding lips) and neck when radical surgical treatment or radiation therapy is not possible
9. Metastases of breast and stomach cancer
10. Colon cancer
11. Prostate cancer
12. Lung cancer
13. Ovarian cancer
14. Uterine chorionic carcinoma
15. Cervical cancer (to improve the effectiveness of radiation therapy)

Contraindications:

1. Hypersensitivity
2. Acute renal or liver failure
3. Thrombocytopenia
4. Severe leukopenia
5. Profound anemia
6. Pregnancy
7. Lactation

Side effect:

1. Myelosuppression (as the first sign of leukopenia, pancytopenia)
2. Dyspeptic disorders
3. Stomatitis
4. Fever
5. Headache
6. Dizziness
7. Disorientation
8. Hallucinations
9. Interstitial nephritis
10. Hyperuricemia
11. Increased levels of transaminases in blood serum
12. Alopecia
13. Facial erythema
14. Maculopapular rash
15. Rarely - diffuse infiltrative lung lesions, allergic skin reactions

Interaction:

1. Increases the effect of cytarabine, weakens the effect of 5-fluorouracil and methotrexate
2. Increases (mutually) the myelotoxicity of drugs that suppress bone marrow function
3. The risk of developing nephropathy increases when co-administered with uricosuric drugs.
4. In combination with antidepressants, antihistamines, sedatives, hypnotics, narcotic drugs and alcohol, it enhances the inhibition of reaction speed

Overdose:
No data.

Special instructions:

1. Caution should be exercised when prescribing to elderly people and children, patients who have previously received radiation or cytostatic therapy
2. Correction of deep anemia is indicated before starting treatment
3. Regular blood tests are required during treatment
4. Dynamic monitoring of the levels of uric acid, creatinine, and transaminases is also recommended
5. During treatment, patients should drink sufficient fluids

Literature:
Encyclopedia of Medicines 2003